阿尔茨海默病筛查对老年人家属的获益与危害:一项随机对照试验的研究方案
本研究为一项随机对照试验方案,旨在评估阿尔茨海默病及相关痴呆(ADRD)筛查对家庭照护者的潜在获益或危害,并比较两种筛查后诊断评估与管理策略的效果。计划纳入1800对老年人与家属配对,随机分为仅筛查组、筛查加综合照护组和无筛查对照组,随访24个月,主要结局为家属生活质量。
要点
- ADRD筛查对家庭照护者的获益与危害尚不明确,USPSTF暂不支持初级保健常规筛查。
- COADS试验将1800对配对随机分为仅筛查、筛查加综合照护和对照组三组。
- 主要结局为家属生活质量,次要结局包括情绪、焦虑、照护准备和自我效能。
核心结论
- 研究假设筛查组照护者在24个月时健康相关生活质量更高、抑郁和焦虑症状更轻、照护准备更充分且自我效能更高。
- 研究结果将为美国国家阿尔茨海默病计划、USPSTF及其他组织的ADRD筛查和早期检测政策提供直接依据。
研究设计与样本
- COADS为随机对照试验,计划纳入1800对老年人与家庭照护者配对。
- 配对随机分为三组(每组n=600):仅筛查组、筛查加综合照护组和无筛查对照组。
主要发现
- 仅筛查组在基线接受ADRD筛查并告知结果,筛查阳性者获得当地诊断随访资源列表。
- 筛查加综合照护组在基线接受ADRD筛查并告知结果,筛查阳性者被转介至痴呆协作照护项目进行诊断评估和潜在照护。
- 对照组不接受筛查。
- 在基线及第6、12、18、24个月测量家属生活质量(主要结局)及情绪、焦虑、照护准备和自我效能(次要结局)。
- 在第6、12、18、24个月检查老年人与家属之间抑郁和焦虑症状的一致性,并比较两种筛查后诊断评估与管理策略的效果。
临床怎么用
- 该研究方案尚不提供临床实践推荐,其结果预期将影响ADRD筛查和早期检测相关政策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple national expert panels have identified early detection of Alzheimer's disease and related dementias (ADRD) as a national priority. However, the United States Preventive Services Task Force (USPSTF) does not currently support screening for ADRD in primary care given that the risks and benefits are unknown. The USPSTF stresses the need for research examining the impact of ADRD screening on family caregiver outcomes. METHODS: The Caregiver Outcomes of Alzheimer's Disease Screening (COADS) is a randomized controlled trial that will examine the potential benefits or harms of ADRD screening on family caregivers. It will also compare the effectiveness of two strategies for diagnostic evaluation and management after ADRD screening. COADS will enroll 1800 dyads who will be randomized into three groups (n = 600/group): the 'Screening Only' group will receive ADRD screening at baseline and disclosure of the screening results, with positive-screen participants receiving a list of local resources for diagnostic follow-up; the 'Screening Plus' group will receive ADRD screening at baseline coupled with disclosure of the screening results, with positive-screen participants referred to a dementia collaborative care program for diagnostic evaluation and potential care; and the control group will receive no screening. The COADS trial will measure the quality of life of the family member (the primary outcome) and family member mood, anxiety, preparedness and self-efficacy (the secondary outcomes) at baseline and at 6, 12, 18 and 24 months. Additionally, the trial will examine the congruence of depressive and anxiety symptoms between older adults and family members at 6, 12, 18 and 24 months and compare the effectiveness of two strategies for diagnostic evaluation and management after ADRD screening between the two groups randomized to screening (Screening Only versus Screening Plus). DISCUSSION: We hypothesize that caregivers in the screening arms will express higher levels of health-related quality of life, lower depressive and anxiety symptoms, and better preparation for caregiving with higher self-efficacy at 24 months. Results from this study will directly inform the National Plan to Address Alzheimer's Disease, the USPSTF and other organizations regarding ADRD screening and early detection policies. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03300180. Registered on 3 October.
引用
- Fowler NR, Head KJ, Perkins AJ, et al. Examining the benefits and harms of Alzheimer's disease screening for family members of older adults: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32075686. doi:10.1186/s13063-019-4029-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。